Pirfenidone and PDE4B Inhibitor Combination for Better PF-ILD Tolerability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for progressive fibrosing interstitial lung diseases (PF-ILD), such as idiopathic pulmonary fibrosis (IPF), either nintedanib or pirfenidone, can only slow down disease progression but not stop or reverse symptoms, and their combination leads to significant gastrointestinal side effects, reducing patient compliance.
Innovation Solution
A combination therapy of a PDE4B inhibitor of formula III administered at 18 mg twice daily with either nintedanib or pirfenidone, in therapeutically effective doses, to enhance therapeutic efficacy while minimizing gastrointestinal side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with nintedanib and pirfenidone is used, then therapeutic efficacy is improved, but gastrointestinal side effects increase
Solution Approach 1:
The patent segments the combination therapy into two distinct parts: a PDE4 inhibitor component and an antifibrotic component (nintedanib or pirfenidone). This segmentation allows for optimized dosing of each component, reducing gastrointestinal side effects while maintaining therapeutic efficacy. The PDE4 inhibitor is administered at 18 mg twice daily, which is a specific optimized dose that balances effectiveness with tolerability.
Solution Approach 2:
The patent applies parameter changes by optimizing the dosage of the PDE4 inhibitor to 18 mg twice daily, which represents a specific parameter optimization. This dosage was determined to provide the best balance between therapeutic efficacy and minimizing gastrointestinal adverse events when combined with antifibrotic therapy.
2Reliability
If combination therapy with nintedanib and pirfenidone is used, then disease progression control is improved, but patient compliance decreases
Solution Approach 1:
By segmenting the therapy into a PDE4 inhibitor plus a single antifibrotic agent (either nintedanib or pirfenidone, but not both), the patent reduces treatment complexity. This segmentation makes the regimen more manageable for patients, improving compliance while still providing enhanced disease progression control compared to monotherapy.
Solution Approach 2:
The patent employs a fixed-dose formulation of the PDE4 inhibitor at 18 mg twice daily, which simplifies dosing instructions and improves patient compliance. The specific fixed dosage eliminates the need for complex dose adjustments, making the treatment regimen more accessible and easier to follow for patients.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The invention concerns an oral pharmaceutical composition comprising • either 18 mg or 9 mg of the PDE4B-inhibitor of formula (III), • a therapeutically effective dose of a second active agent selected from the group consisting of nintedanib or pirfenidone and • optionally, one or more pharmaceutically acceptable carriers or excipients for the treatment of a patient suffering from a progressive fibrosing interstitial lung disease (PF-ILD), wherein this oral pharmaceutical composition is to be administered to said patient twice daily. The invention further concerns the use of the PDE4B-inhibitor of formula (III) for preparing an oral pharmaceutical composition comprising either18 mg or 9 mg of the PDE4B-inhibitor of formula (III) for use in a method of treating a patient suffering from one or more Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), wherein said oral pharmaceutical composition is to be orally administered twice daily to said patient in combination with a therapeutically effective amount of a therapeutically effective dose of a second active agent selected from the group consisting of nintdanib and pirfenidone.